CLAIMS

1. An immunogenic composition comprising an antigen and one or more immunostimulants, wherein the concentration of sodium chloride ~~or the ionic strength of said composition~~ is less than 100mM, wherein the antigen is PRAME, wherein the immunostimulant is a saponin, a TLR-4 agonist or a mixture thereof, and wherein the immunostimulant is in the form of liposomes.

~~2. An immunogenic composition as claimed in claim 1 wherein the antigen or antigenic preparation is any antigen which precipitates, coagulates or aggregates after being dissolved in a solution comprising a concentration of sodium chloride or with an ionic strength greater than 5mM, 10mM, 15mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM or 100mM.~~

~~3. An immunogenic composition comprising of claim 1 or 2, wherein the concentration of sodium chloride is less than 100mM and wherein the antigen is PRAME or a fragment or derivative thereof.~~

~~4. An immunogenic composition comprising of claim 1 or 2, wherein the concentration of sodium chloride is less than 100mM and wherein the antigen is NY-ESO-1 or a fragment or derivative thereof.~~

~~5. An immunogenic composition as claimed in any one of claims 1 to 4 wherein the concentration of sodium chloride or ionic strength is less than about 100mM, 90mM, 80mM, 70mM, 60mM, 50mM, 40mM, 30mM, 20mM, or 15mM.~~

~~6. An immunogenic composition as claimed in claim 5 wherein the concentration of sodium chloride or ionic strength is less than 10mM.~~

~~7. An immunogenic composition as claimed in claim 6 wherein the concentration of sodium chloride or ionic strength is less than 5mM.~~

~~8. An immunogenic composition as claimed in claim 7 which contains essentially no sodium chloride.~~

~~9~~ 2. ~~An~~ The immunogenic composition according to ~~any preceding~~ claim 1 further comprising a non-ionic isotonicity agent.

~~10. An immunogenic composition according to claim 9 wherein the non-ionic isotonicity agent is a polyol.~~

~~11. An immunogenic composition according to claim 10 wherein the polyol is sorbitol.~~

~~12. The immunogenic composition of claim 11 wherein the concentration of sorbitol is between about 3% and about 15% (w/v).~~

~~13. The immunogenic composition of claim 12 wherein the concentration of sorbitol is between about 4% and about 10% (w/v).~~

~~14~~ 3. ~~An~~ The immunogenic composition according to ~~any preceding~~ claim 2 comprising about 5mM sodium choloride and between 5% and 6% w/v sorbitol.

~~15. An immunogenic composition of any one of claims 1 to 14 comprising one or more immunostimulants.~~

~~16. The immunogenic composition of claim 15 wherein the immunostimulant is a saponin and/or a TLR-4 agonist.~~

~~17. The immunogenic composition of claim 16 wherein the immunostimulant(s) is/are in the form of liposomes.~~

~~18~~ 4. The immunogenic composition of any one of claims 1 to 3 ~~claim 16 or 17~~ wherein the saponin is QuilA or a derivative thereof.

~~19~~ 5. The immunogenic composition of claim 4 ~~18~~ wherein the derivative of QuilA is QS21.

~~20~~ 6. The immunogenic composition of any one of claims 1 to 5 ~~16 to 19~~ wherein the TLR-4 agonist is 3D-MPL.

~~21~~ 7. ~~An~~ The immunogenic according to any one of claims 1 to 6 ~~to 20~~ further comprising a CpG oligonucleotide.

~~22~~ 8. The immunogenic composition of any one of claims 1 to 7 ~~21~~ for use in medicine.

~~23~~ 9. The immunogenic composition of any one of claims 1 to 7 ~~21~~ for use in the treatment of cancer.

~~24~~ 10. Use of an immunogenic composition of any one of claims 1 to 7 ~~21~~ in the manufacture of a medicament for the treatment of cancer.

~~25~~ 11. A process for making an immunogenic composition as claimed in any one of claims 1 to 7 ~~22~~ comprising the steps:

a. Lyophilising an antigen, optionally with an immunostimulatory oligonucleotide; and

b. Resconstituting the lyophilised composition of step a) with an aqueous adjuvant composition comprising a TLR-4 agonist, and a saponin in a liposomal formulation and a non- ionic isotonicity agent comprising sorbitol, wherein the concentration of NaCl or ionic strength is less than 100mM ~~90mM, 80mM, 70mM, 60mM, 50mM, 40mM, 30mM, 20mM, 15mM or 10mM~~.

~~26~~ 12. A kit comprising:

a. a lyophilised antigen, optionally co-lyophilised with CpG; and

b. an aqueous adjuvant composition comprising a TLR-4 agonist, and a saponin in a liposomal formulation and a non-ionic isotonicity agent comprising sorbitol, wherein the concentration of NaCl or ionic strength is less than 100mM~~, 90mM, 80mM, 70mM, 60mM, 50mM, 40mM, 30mM, 20mM, 15mM or 10mM~~.

~~27. The process of claim 26 or a kit according to claim 27 wherein the aqueous adjuvant composition comprises a TLR-4 agonist, and a saponin in a liposomal formulation and a non-ionic isotonicity agent.~~

~~28. The process or kit of claim 27 wherein the non-ionic isotonicity agent is sorbitol.~~

~~29. The process or kit of claim 28 wherein the concentration of sorbitol is between about 3% and 15% (w/v), 4% and 10% (w/v) or between about 5% and 6% (w/v).~~

~~30. The process or kit of claims 27 or 28 wherein the saponin is QS21.~~

~~31. The process or kit of any one claims 27 to 30 wherein the TLR-4 agonist is 3D-MPL.~~

~~32. A process or kit of any one of claims 25 to 31 wherein the concentration of NaCl in the aqueous adjuvant composition is about 5mM.~~

~~33. The process or kit of any one of claims 25 to 32 wherein the antigen precipitates, coagulates or aggregates after being dissolved in a solution comprising a concentration of sodium chloride or wherein the ionic strength of the solution is greater than 10mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM or 100mM.~~

~~34. The process or kit of any one of claims 25 to 33 wherein the antigen is selected from PRAME or NY-ESO-1.~~

13. An immunogenic composition comprising an antigen and one or more immunostimulants, wherein the concentration of sodium chloride is less than 100mM, wherein the antigen is NY-ESO-1, wherein the immunostimulant is a saponin, a TLR-4 agonist or a mixture thereof, and wherein the immunostimulant is in the form of liposomes.

14. The immunogenic composition according to claim 13 further comprising a non- ionic isotonicity agent.

15. The immunogenic composition according to claim 14 comprising about 5mM sodium chloride and between 5% and 6% w/v sorbitol.

16. The immunogenic composition of any one of claims 13 to 15, wherein the saponin is QuilA or a derivative thereof.

17. The immunogenic composition of claim 16 wherein the derivative of QuilA is QS21.

18. The immunogenic composition of any one of claims 13 to 17 wherein the TLR-4 agonist is 3D-MPL.

19. The immunogenic composition according to any one of claims 13 to 18 further comprising a CpG oligonucleotide.

20. The immunogenic composition of any one of claims 13 to 19 for use in medicine.

21. The immunogenic composition of any one of claims 13 to 19 for use in the treatment of cancer.

22. Use of an immunogenic composition of any one of claims 13 to 19 in the manufacture of a medicament for the treatment of cancer.

23. A process for making an immunogenic composition as claimed in any one of claims 13 to 19 comprising the steps

a. lyophilising an antigen, with an immunostimulatory oligonucleotide; and

b. reconstituting the lyophilized composition of step a) with an aqueous adjuvant composition comprising a TLR-4 agonist, and a saponin in a liposomal formulation and a non- ionic isotonicity agent comprising sorbitol, wherein the concentration of NaCl or ionic strength is less than 100mM.